Genmab — Juni 2013
-
programmet bliver mere detaljeret i løbet af i år
-
data skal ses i lyset af at patienterne havde været så meget igennem
-
behandlingerne inden dara:
5,2 i gennemsnit -
Det går stærkt. Så Humax - TF
-
de taler allerede med myndighederne
-
kører det ind i klinikken h2
-
Om IND ?
-
IND planlagt til 2013
-
Siger han hvilke indikationer?
-
står på slide no 13
-
Eller bare solid tumors ?
-
lyder som bare solid - check sliden. Der er nævtnt 5-6 stykker
-
95% yield på duobody platform
-
may well become the leading bispecific technology
-
Yield? Er det cost margin improvement? de 95%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind